Page 226 - Quantitative Imaging of Small Tumours with Positron Emission Tomography

45. Grubmuller B, Senn D, Kramer G, et al. Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063-1072. 46. Kuten J, Sarid D, Yossepowitch O, Mabjeesh NJ, Even-Sapir E. [(68)Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up? EJNMMI Res. 2019;9:84. 47. Ferraro DA, Muehlematter UJ, Garcia Schuler HI, et al. (68)Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2019. 48. Zamboglou C, Carles M, Fechter T, et al. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics. 2019;9:2595-2605. 49. Boustani AM, Pucar D, Saperstein L. Molecular imaging of prostate cancer. Br J Radiol. 2018;91:20170736. 50. Alonso O, Dos Santos G, Garcia Fontes M, Balter H, Engler H. (68)Ga-PSMA and (11)C-Choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttle. Eur J Hybrid Imaging. 2018;2:9. 51. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga- labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20. 52. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015;56:1185-1190. 53. Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215:159-175. 54. Donin NM, Reiter RE. Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med. 2018;59:177-182. 55. Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA Ligands for PET Imaging of Prostate Cancer. J Nucl Med. 2017;58:1545-1552. 56. Wondergem M, Jansen BHE, van der Zant FM, et al. Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1911-1918. 57. Calais J, Ceci F, Eiber M, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286-1294. 58. Song H, Harrison C, Duan H, et al. Prospective Evaluation in an Academic Center of (18)F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management. J Nucl Med. 2019. 59. Cytawa W, Seitz AK, Kircher S, et al. (68)Ga-PSMA I&T PET/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2019. 60. van Kalmthout LWM, van Melick HHE, Lavalaye J, et al. Prospective Validation of Gallium-68 PSMA- PET/CT in Primary Staging of Prostate Cancer Patients. J Urol. 2019:101097JU0000000000000531. 61. Herlemann A, Wenter V, Kretschmer A, et al. (68)Ga-PSMA Positron Emission Tomography/ Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol. 2016;70:553-557. 11 62. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195:1436-1443. 63. Hatt M, Lucia F, Schick U, Visvikis D. Multicentric validation of radiomics findings: challenges and opportunities. EBioMedicine. 2019;47:20-21. 64. Heinzel A, Boghos D, Mottaghy FM, et al. (68)Ga-PSMA PET/CT for monitoring response to (177) Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1054-1062. Summarizing discussion 225